Table 2 Diagnostic criteria for daptomycin or drug induced eosinophilia
FDA guidance for attributing eosinophilic pneumonia to daptomycin | Solomon and Schwartz criteria for drug or toxin induced eosinophilic pneumonia |
|---|---|
Exposure to daptomycin | Presence of eosinophilic pneumonia on lung biopsy or BAL (> 25%) in the setting of parenchymal infiltrates |
Fever | Presence of a potential candidate drug or toxin in an appropriate time frame |
Dyspnea with increased oxygen requirement (or mechanical ventilation requirement) | No other cause of eosinophilic pneumonia such as fungal or parasitic infection |
New infiltrates on chest X-ray or computed tomography (CT) scan | Clinical improvement after cessation of the drug or toxin |
Bronchoalveolar lavage (BAL) with > 25% eosinophils | Recurrence of eosinophilic pneumonia with rechallenge to the drug or toxin |
Clinical improvement following daptomycin withdrawal | Â |